892 ABL503 (TJ-L14B), PD-L1x4–1BB bispecific antibody induces superior anti-tumor activity by PD-L1-dependent 4–1BB activation with the increase of 4–1BB+CD8+ T cells in tumor microenvironment

• Wenqing Jiang,
• Zhengyi Wang,
• Jaeho Jung,
• Hyunjoo Kim,
• Eunsil Sung,
• Jaehyoung Jeon,
• Youngkwang Kim,
• Shinai Lee,
• Yangmi Lim,
• Jonghwa Won,
• Uijung Jung,
• Hyung-Seung Jin,
• Gihoon You

Affiliations

Wenqing Jiang

1 Department of Respiratory Diseases, Qingdao Haici Hospital, Qingdao, China

Zhengyi Wang

8I-Mab Biopharma, Gaithersburg, MD, USA

Jaeho Jung

3Department of Ophthalmology, Pusan National University Yangsan Hospital, Yangsan, South Korea

Hyunjoo Kim

2Department of Occupational and Environmental Medicine, Ewha Womans University Mokdong Hospital, South Korea

Eunsil Sung

ABL Bio Inc, Seongnam, Korea

Jaehyoung Jeon

ABL Bio Inc, Seongnam, Korea

Youngkwang Kim

ABL Bio Inc, Seongnam, Korea

Shinai Lee

ABL Bio Inc, Seongnam, Korea

Yangmi Lim

ABL Bio Inc, Seongnam, Korea

Jonghwa Won

ABL Bio Inc, Seongnam, Korea

Uijung Jung

1ABL Bio Inc., Seongnam, Korea, Republic of

Hyung-Seung Jin

2Asan Medical Center, Seoul, Korea, Republic of

Gihoon You

1ABL Bio Inc., Seongnam, Korea, Republic of